Synthesis and Evaluation of Antidiabetic Potential of Gliptin‐based Hybrid Scaffolds
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202401890 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Shaikh Yahya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, 110062, New Delhi. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Molecular Docking Simulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Indian Council of Medical Research (ICMR).
Abstract (Originalsprache)
Dipeptidyl peptidase‐4 (DPP4) inhibitors are promising therapeutic targets for the treatment of a catastrophic disease, especially diabetes mellitus (DM), which contributed to a massive rate of mortality. This research work succinctly covers the significance and vital role of gliptins in diabetes management and in the potential areas of further antidiabetic research, making it a strong drug candidate for antidiabetic drug development. We illustrated herein molecular docking, synthesis, and biological evaluation of selected potent synthesized molecules. Additionally, all the potent compounds were characterized by means of MASS and NMR spectral analysis, whereas the purity of these molecules were assessed by HPLC method. In order to determine the efficacy and cytotoxicity of synthesized gliptin‐based scaffolds, in‐vitro anti‐oxidant and MTT assays with the implantation of DPPH and THP‐1 cell lines, respectively, were performed. The results data disclose the anti‐oxidant and biosafety potential of the newly schemed compounds. Based on in‐vitro screening outcomes, only a derivative that exhibited potent efficacy was selected and subjected to an in‐vivo study. Among them, compounds 6 and 12 are the most potent ones, which exhibited % radical scavenge of 89 .38 % and 91 .58 % related to standard ascorbic acid (91 .58 % ) . Surprisingly, these compounds also exhibited excellent anti‐diabetic efficacy at a dose of 4 mg/kg in an in‐vivo animal model. In conclusion, all studies suggested that the titled molecules could be promising lead compounds for the treatment of patients with type 2 diabetes mellitus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, 110062, New Delhi.
- Y. B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Rauza Baugh, Aurangabad, 431001, India.
- Department of Pharmaceutical Chemistry, Deogiri College, Aurangabad, Maharashtra, 431001, India.
ORCID-Profile: Shaikh Yahya, Vivek Kumar Gour, Prathamesh Deshpande, Akram Choudhary, M Shahar Yar
Förderung
- Indian Council of Medical Research (ICMR)
Zitieren
APA
Yahya, S., Gour, V. K., Sangshetti, J., Deshpande, P., Shafeeque, M., Sharma, N., Choudhary, A., & Shahar Yar, M. (2025). Synthesis and Evaluation of Antidiabetic Potential of Gliptin‐based Hybrid Scaffolds. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202401890
Vancouver
Yahya S, Gour VK, Sangshetti J, Deshpande P, Shafeeque M, Sharma N, et al. Synthesis and Evaluation of Antidiabetic Potential of Gliptin‐based Hybrid Scaffolds. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202401890
BibTeX
@article{Yahya2025,
author = {Yahya, Shaikh and Gour, Vivek Kumar and Sangshetti, Jaiprakash and Deshpande, Prathamesh and Shafeeque, Mohd and Sharma, Nisha and Choudhary, Akram and Shahar Yar, M},
title = {Synthesis and Evaluation of Antidiabetic Potential of Gliptin‐based Hybrid Scaffolds},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202401890}
}
EUVIMED